Evidence map›Paper›PMID 38140689›Full record

ArticleViruses2023

Genomic Analysis of Influenza A and B Viruses Carrying Baloxavir Resistance-Associated Substitutions Serially Passaged in Human Epithelial Cells.

Brady T Hickerson, Bruce K Huang, Svetlana N Petrovskaya, Natalia A Ilyushina

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Brady T HickersonDivision of Biotechnology Review and Research II, Food and Drug Administration, Silver Spring, MD 20993, USA.
Bruce K HuangDivision of Biotechnology Review and Research II, Food and Drug Administration, Silver Spring, MD 20993, USA.
Svetlana N PetrovskayaDivision of Biotechnology Review and Research III, Food and Drug Administration, Silver Spring, MD 20993, USA.
Natalia A IlyushinaDivision of Biotechnology Review and Research II, Food and Drug Administration, Silver Spring, MD 20993, USA.
United States Food and Drug Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Baloxavir marboxil (baloxavir) is an FDA-approved inhibitor of the influenza virus polymerase acidic (PA) protein. Here, we used next-generation sequencing to compare the genomic mutational profiles of IAV H1N1 and H3N2, and IBV wild type (WT) and mutants (MUT) viruses carrying baloxavir resistance-associated substitutions (H1N1-PA I38L, I38T, and E199D; H3N2-PA I38T; and IBV-PA I38T) during passaging in normal human bronchial epithelial (NHBE) cells. We determined the ratio of nonsynonymous to synonymous nucleotide mutations (d

Indexed as

Herpesvirus 1, CercopithecineInfluenza A Virus, H1N1 SubtypeInfluenza, HumanThiepinsAntiviral AgentsDibenzothiepinsEpithelial CellsGenomicsHumansInfluenza A Virus, H3N2 SubtypeMorpholinesNucleotidyltransferasesOxazinesPyridinesPyridonesTriazinesAntiviral AgentsbaloxavirDibenzothiepinsMorpholinesNucleotidyltransferasesOxazinesPyridinesPyridonesThiepinsTriazinesViral Proteinsbaloxavir resistanceinfluenzapolymerase substitutionsviral mutation

Identifiers

PMID38140689
PMCPMC10748225
OpenAlexW4389893971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.